462 related articles for article (PubMed ID: 30813769)
41. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
[TBL] [Abstract][Full Text] [Related]
42. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
[TBL] [Abstract][Full Text] [Related]
43. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment.
Ornello R; Zelli V; Compagnoni C; Caponnetto V; De Matteis E; Tiseo C; Tessitore A; Sacco S
J Headache Pain; 2024 May; 25(1):80. PubMed ID: 38755568
[TBL] [Abstract][Full Text] [Related]
45. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.
Fernández-Bravo-Rodrigo J; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Flor-García A; Barreda-Hernández D; Pascual-Morena C
Eur J Pharmacol; 2024 Aug; 976():176702. PubMed ID: 38823758
[TBL] [Abstract][Full Text] [Related]
46. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.
Ornello R; Tiseo C; Frattale I; Perrotta G; Marini C; Pistoia F; Sacco S
J Headache Pain; 2019 Oct; 20(1):99. PubMed ID: 31666008
[TBL] [Abstract][Full Text] [Related]
47. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
Lanteri-Minet M; Fabre R; Martin C; Pradat K; Alchaar A; Bozzolo E; Duchene ML; Van Obberghen EK; Donnet A; Fontaine D
J Headache Pain; 2023 Nov; 24(1):152. PubMed ID: 37940860
[TBL] [Abstract][Full Text] [Related]
48. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
49. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
Dodick DW
Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
[TBL] [Abstract][Full Text] [Related]
50. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
51. Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab.
de Vries T; Rubio-Beltrán E; van den Bogaerdt A; Dammers R; Danser AHJ; Snellman J; Bussiere J; MaassenVanDenBrink A
Br J Pharmacol; 2024 Jun; 181(12):1720-1733. PubMed ID: 38320397
[TBL] [Abstract][Full Text] [Related]
52. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
Ashina M; Kudrow D; Reuter U; Dolezil D; Silberstein S; Tepper SJ; Xue F; Picard H; Zhang F; Wang A; Zhou Y; Hong F; Klatt J; Mikol DD
Cephalalgia; 2019 Dec; 39(14):1798-1808. PubMed ID: 31707815
[TBL] [Abstract][Full Text] [Related]
53. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
Raffaelli B; Reuter U
Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
[TBL] [Abstract][Full Text] [Related]
54. Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed.
Vo P; Wen S; Martel MJ; Mitsikostas D; Reuter U; Klatt J
Cephalalgia; 2019 Apr; 39(5):608-616. PubMed ID: 30231626
[TBL] [Abstract][Full Text] [Related]
55. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
56. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
Giannouchos TV; Mitsikostas DD; Ohsfeldt RL; Vozikis A; Koufopoulou P
Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
[TBL] [Abstract][Full Text] [Related]
57. Migraine treatment: the doors for the future are open, but with caution and prudence.
Krymchantowski AV; Krymchantowski AGF; Jevoux CDC
Arq Neuropsiquiatr; 2019 Feb; 77(2):115-121. PubMed ID: 30810596
[TBL] [Abstract][Full Text] [Related]
58. Central effects of erenumab in migraine patients: An event-related functional imaging study.
Ziegeler C; Mehnert J; Asmussen K; May A
Neurology; 2020 Nov; 95(20):e2794-e2802. PubMed ID: 32917805
[TBL] [Abstract][Full Text] [Related]
59. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine.
Bussiere JL; Davies R; Dean C; Xu C; Kim KH; Vargas HM; Chellman GJ; Balasubramanian G; Rubio-Beltran E; MaassenVanDenBrink A; Monticello TM
Regul Toxicol Pharmacol; 2019 Aug; 106():224-238. PubMed ID: 31085251
[TBL] [Abstract][Full Text] [Related]
60. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
